Natixis Dyne Therapeutics, Inc. Transaction History
Natixis
- $17.6 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding DYN
# of Institutions
210Shares Held
102MCall Options Held
234KPut Options Held
238K-
Atlas Venture Life Science Advisors, LLC8.02MShares$241 Million35.54% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$222 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.86MShares$206 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY6.82MShares$204 Million3.9% of portfolio
-
Janus Henderson Group PLC London, X06.81MShares$204 Million0.13% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.55B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...